Mavrilimumab is under clinical development by Kiniksa Pharmaceuticals and currently in the Phase I, Phase II and Phase III in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Mavrilimumab’s likelihood of approval (LoA) and phase transition for Inflammation took place on 21 Mar 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Mavrilimumab Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Mavrilimumab overview

Mavrilimumab (CAM-3001, KPL-301) is under development for the treatment of  giant cell arteritis, autoimmune diseases and large B-cell lymphoma and CAR T induced cytokine release syndrome, rheumatoid arthritis and covid-19 associated acute respiratory distress syndrome. It is also under development for severe pneumonia of COVID-19 and hyperinflammation. The drug candidate is administered subcutaneously and intravenously. It is a human monoclonal antibody targeting the alpha subunit of the granulocyte macrophage-colony stimulating factor receptor alpha (GM-CSFR alpha).

Kiniksa Pharmaceuticals overview

Kiniksa Pharmaceuticals (Kiniksa) is a biopharmaceutical company that discovers, acquires, develops and commercializes medicines to treat autoinflammatory and autoimmune diseases. The company’s pipeline product portfolio includes Rilonacept drug for the treatment of recurrent pericarditis; mavrilimumab, against giant cell arteritis, COVID-19 and hyper inflammation; vixarelimab, targeting prurigo nodularis and diseases characterized by chronic pruritus; KPL-404, a monoclonal antibody to treat T-cell dependent, B-Cell–mediated indications. It develops medicines in the therapeutic areas of cardiovascular, dermatology and autoimmune diseases. The company has an operational presence in Massachusetts and California, the US; and London, the UK. Kiniksa is headquartered in Hamilton, Bermuda.

Quick View Mavrilimumab LOA Data

Report Segments
  • Innovator
Drug Name
  • Mavrilimumab
Administration Pathway
  • Intravenous
  • Subcutaneous
Therapeutic Areas
  • Cardiovascular
  • Immunology
  • Infectious Disease
  • Oncology
  • Respiratory
Key Developers
Highest Development Stage
  • Phase III

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.